We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
Cap. Flow
-$140M
Cap. Flow %
-9.32%
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
2
OGN icon
Organon & Co
OGN
+$23M
3
CYH icon
Community Health Systems
CYH
+$19.2M
4
RCM icon
R1 RCM Inc. Common Stock
RCM
+$18.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$71.3M
2
GSK icon
GSK
GSK
+$28.4M
3
TGTX icon
TG Therapeutics
TGTX
+$27.2M
4
ELV icon
Elevance Health
ELV
+$20.5M
5
CTLT icon
CATALENT, INC.
CTLT
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.27%
2 Miscellaneous 33.54%
3 Industrials 1.14%
4 Financials 0.05%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$107M 7.13%
250,000
+150,000
+150% +$62.6M
2021 Q1
1 quarter
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$487B
$88.6M 5.91%
+250,000
New +$84.1M
2021 Q2
0 quarters
UTHR icon
3
United Therapeutics
UTHR
$23.2B
$79.5M 5.3%
442,945
-43,584
-9% -$8.3M
2020 Q2
4 quarters
AMRN icon
4
Amarin Corp
AMRN
$244M
$73M 4.87%
833,474
-11,366
-1% -$1.12M
2018 Q1
13 quarters
ARKG icon
5
ARK Genomic Revolution ETF
ARKG
$2.09B
$71.5M 4.77%
773,480
-33,452
-4% -$2.84M
2021 Q1
1 quarter
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$62.4M 4.16%
666,738
-28,721
-4% -$2.64M
2020 Q2
4 quarters
AZN icon
7
AstraZeneca
AZN
$259B
$59M 3.94%
492,861
-3,297
-0.7% -$362K
2019 Q4
6 quarters
CYH icon
8
Community Health Systems
CYH
$422M
$59M 3.93%
3,821,729
+1,415,895
+59% +$19.2M
2020 Q4
2 quarters
GSK icon
9
CALL
GSK
GSK
$98.2B
$55.9M 3.73%
1,122,960
+199,680
+22% +$9.59M
2020 Q4
2 quarters
DHR icon
10
Danaher
DHR
$163B
$55M 3.66%
230,907
+30,649
+15% +$6.8M
2018 Q3
11 quarters
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$42M 2.8%
335,045
+93,064
+38% +$11.7M
2021 Q1
1 quarter
BIIB icon
12
CALL
Biogen
BIIB
$34.8B
$40M 2.67%
+115,600
New +$35M
2021 Q2
0 quarters
TEVA icon
13
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$37.7M 2.51%
3,804,405
-550,351
-13% -$5.83M
2020 Q3
3 quarters
VRTX icon
14
CALL
Vertex Pharmaceuticals
VRTX
$129B
$34.9M 2.33%
173,300
+113,300
+189% +$23.7M
2021 Q1
1 quarter
AVTR icon
15
Avantor
AVTR
$10.9B
$34.6M 2.31%
974,637
+15,650
+2% +$506K
2020 Q4
2 quarters
BMY icon
16
Bristol-Myers Squibb
BMY
$124B
$32M 2.13%
+478,328
New +$31.2M
2021 Q2
0 quarters
ASND icon
17
Ascendis Pharma A/S
ASND
$14.9B
$31.8M 2.12%
241,774
-70,093
-22% -$9.34M
2017 Q4
14 quarters
QGEN icon
18
Qiagen
QGEN
$9.53B
$31.5M 2.1%
613,962
+185,135
+43% +$9.56M
2020 Q2
4 quarters
FATE icon
19
Fate Therapeutics
FATE
$231M
$30.1M 2%
346,347
+24,587
+8% +$1.98M
2018 Q4
10 quarters
OCDX
20
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$29.9M 1.99%
1,394,284
+19,056
+1% +$387K
2021 Q1
1 quarter
AMRX icon
21
Amneal Pharmaceuticals
AMRX
$6.7B
$28.8M 1.92%
5,624,725
+869,245
+18% +$4.94M
2020 Q2
4 quarters
NVST icon
22
Envista
NVST
$3.77B
$28.3M 1.89%
656,098
-76,586
-10% -$3.32M
2020 Q4
2 quarters
XBI icon
23
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.9B
$27.1M 1.8%
+200,000
New +$26.3M
2021 Q2
0 quarters
OGN icon
24
Organon & Co
OGN
$3.61B
$21.2M 1.41%
+699,696
New +$23M
2021 Q2
0 quarters
ARKG icon
25
CALL
ARK Genomic Revolution ETF
ARKG
$2.09B
$18.4M 1.23%
+199,000
New +$16.9M
2021 Q2
0 quarters
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.

  • Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
  • Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
  • Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
  • Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
  • Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.